DUVELISIB - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for duvelisib and what is the scope of patent protection?
Duvelisib
is the generic ingredient in one branded drug marketed by Secura and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Duvelisib has one hundred and forty-seven patent family members in thirty-four countries.
Summary for DUVELISIB
International Patents: | 147 |
US Patents: | 4 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 66 |
Clinical Trials: | 40 |
Patent Applications: | 1,911 |
Drug Prices: | Drug price trends for DUVELISIB |
What excipients (inactive ingredients) are in DUVELISIB? | DUVELISIB excipients list |
DailyMed Link: | DUVELISIB at DailyMed |
Recent Clinical Trials for DUVELISIB
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Secura Bio, Inc. | Early Phase 1 |
National Cancer Institute (NCI) | Early Phase 1 |
Secura Bio | Early Phase 1 |
US Patents and Regulatory Information for DUVELISIB
EU/EMA Drug Approvals for DUVELISIB
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Secura Bio Limited | Copiktra | duvelisib | EMEA/H/C/005381 Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies. |
Authorised | no | no | no | 2021-05-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for DUVELISIB
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | 351028 | DETERMINADADAS ENTIDADES, COMPOSICIONES Y METODOS QUIMICOS. (CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS.) | See Plans and Pricing |
Israel | 242192 | חומרים כימיים מסוימים, תכשירים ושיטות (Certain chemical entities, compositions and methods) | See Plans and Pricing |
Peru | 20180318 | PROCEDIMIENTO PARA PREPARAR ISOQUINOLINONAS Y FORMAS SOLIDAS DE ISOQUINOLINONAS | See Plans and Pricing |
European Patent Office | 3441392 | COMPOSITION PHARMACEUTIQUE POUR ADMINISTRATION ORALE (A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION) | See Plans and Pricing |
Japan | 2011509259 | See Plans and Pricing | |
European Patent Office | 2456444 | DÉRIVÉ D'ADENINE COMME INHIBITEUR DE PI3K (ADENINE DERIVATIVE AS PI3K INHIBITOR) | See Plans and Pricing |
Ukraine | 109878 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DUVELISIB
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2456444 | 46/2021 | Austria | See Plans and Pricing | PRODUCT NAME: DUVELISIB; REGISTRATION NO/DATE: EU/1/21/1542 (MITTEILUNG) 20210521 |
2456444 | CA 2021 00045 | Denmark | See Plans and Pricing | PRODUCT NAME: DUVELISIB; REG. NO/DATE: EU/1/21/1542 20210521 |
2456444 | 122021000069 | Germany | See Plans and Pricing | PRODUCT NAME: DUVELISIB; REGISTRATION NO/DATE: EU/1/21/1542 20210519 |
2456444 | 132021000000173 | Italy | See Plans and Pricing | PRODUCT NAME: DUVELISIB(COPIKTRA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1542, 20210521 |
2456444 | PA2021526 | Lithuania | See Plans and Pricing | PRODUCT NAME: DUVELISIBAS; REGISTRATION NO/DATE: EU/1/21/1542 20210519 |
2456444 | LUC00237 | Luxembourg | See Plans and Pricing | PRODUCT NAME: DUVELISIB; AUTHORISATION NUMBER AND DATE: EU1/21/1542 20210521 |
2456444 | 301140 | Netherlands | See Plans and Pricing | PRODUCT NAME: DUVELISIB; REGISTRATION NO/DATE: EU/1/21/1542 20210521 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |